Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Cardiac hemangioma

Cardiac hemangioma is a rare benign vascular lesion consisting of a proliferation of vascular channels lined by endothelium, which may involve the endocardium, myocardium, epicardium or pericardium. Its significance derives from the relationship between vascular architecture and location: a small intracavitary lesion may interfere with a valve, whereas an intramural or pericardial mass may cause arrhythmias, compression or effusion. Recognition of the vascular component guides diagnosis and affects the safety of any procedure performed on the lesion.

The tumor has been described from fetal life through old age. Some cases are detected incidentally, whereas others are identified during investigations for dyspnea, chest pain or rhythm disturbances. Its actual frequency in the population remains poorly defined: percentages relative to other primary cardiac tumors depend on classification criteria and on autopsy, echocardiographic or surgical case selection. The compilation by Li and colleagues in 2015 included 200 published cases; the review by Munteanu and colleagues in 2025 analyzed 55 more recent observations. These studies outline the clinical spectrum but are affected by the greater likelihood of publication of unusual presentations and operated patients.
Most knowledge therefore comes from individual cases and small series. For a well-characterized asymptomatic mass, treatment selection requires an individualized assessment of location, growth and operative risk, without turning the frequency of surgery in published reports into a general obligation to resect.

Etiology, classification and pathological anatomy

The mechanisms underlying the development of cardiac hemangioma are incompletely defined. The lesion involves abnormal organization of the vascular compartment, but available evidence does not identify a single molecular cause applicable to every form. Congenital presentations and late diagnoses may reflect different biological pathways. Findings from common infantile cutaneous hemangiomas cannot automatically be applied to every vascular cardiac mass, particularly in adults: location, morphology and natural history must be established before considering treatment derived from experience in other anatomical sites.

Traditional classification distinguishes capillary forms, with closely spaced small vessels, cavernous forms, composed of larger spaces, and forms with arteriovenous components; combinations may occur in the same mass. These terms primarily describe the histological architecture reported in cardiac case series. General vascular-anomaly nomenclature also distinguishes tumors from malformations, so historical names require pathological interpretation and do not necessarily denote a single biological entity. The presence of an arteriovenous channel must likewise be demonstrated rather than inferred solely from intense contrast enhancement.

On gross examination, the lesion may appear reddish, spongy or more compact depending on vessel caliber, blood content and stromal component. Intralesional thrombosis, fibrous organization and hemorrhage can change both its color and its appearance on imaging. The lesion may be well circumscribed or have less distinct boundaries with adjacent tissue. Its vascular nature makes control of feeding vessels important during removal and explains why a simple biopsy may have different consequences from sampling a poorly vascularized mass.

Microscopically, the lumina are lined by mature endothelial cells without the combination of marked atypia, disorganized proliferation and destructive growth characteristic of malignant vascular neoplasms. Endothelial markers such as CD31 and ERG support vascular differentiation but do not establish benignity on their own: assessment rests on architecture and cytology. In complex specimens, specialist evaluation differentiates hemangioma, intermediate vascular lesions, organized thrombus with endothelial proliferation and angiosarcoma.

The lesion may be intracavitary, intramural or predominantly epicardial and pericardial. All cardiac chambers may be affected, and rare valvular lesions have also been described. The site of origin, depth and any connection with the coronary circulation have greater practical importance than a classification based solely on the nearest chamber. Documentation of hemangiomas in other organs or a vascular syndrome prompts broader evaluation, whereas an isolated cardiac lesion does not automatically imply an inherited systemic vascular disorder.

Pathophysiology: space occupation, perfusion and effects on cardiac rhythm

Obstruction occurs when the mass occupies an inflow or outflow tract or reduces the usable volume of a chamber. A mobile endocardial lesion may dynamically interfere with a valve; a more fixed mural growth may persistently narrow the passage. Severity depends on position during the cardiac cycle and the relationship to chamber size. Doppler documents the effect on flow, while anatomical assessment identifies the structure causing the obstruction.

Tumor vascularization may arise from coronary branches or, depending on location, extracardiac vessels. A highly developed network makes surgical vascular control more complex; high-flow communications, if present, may add a hemodynamic burden. Mechanisms that interfere with myocardial perfusion have been described, including vessel compression or unfavorable flow distribution. Attributing ischemia to the mass nevertheless requires agreement among anatomy, symptoms and functional tests, because simply identifying a feeding vessel does not demonstrate coronary steal.

Arrhythmias may occur in intramyocardial lesions owing to disruption of muscular architecture, distortion of conducting tissues or local perfusion changes. They may manifest as ectopic beats, tachycardia or a conduction disorder; the mechanism must be established in the individual patient. A pericardial mass may also produce electrical effects through compression or involvement of adjacent myocardium. Systolic function and arrhythmic risk are therefore related but not interchangeable dimensions.

Pericardial effusion may accompany epicardial or pericardial lesions and become clinically significant when it accumulates rapidly or restricts filling. Bleeding into the lesion or pericardial space may abruptly change a previously stable presentation. Tamponade depends on the pressure exerted on the heart and the rate of accumulation as well as the volume of fluid. This possibility requires attention to the pericardial component on imaging, without assuming that every effusion associated with hemangioma is necessarily hemorrhagic.

The embolic risk mainly concerns rare lesions exposed to intracavitary flow, that are mobile or are associated with superficial thrombus. It is not equally important for all vascular lesions, many of which are confined within the wall. Cerebral or systemic events require a comprehensive search for possible sources and an assessment of whether a causal link with the mass is plausible. Any antithrombotic treatment must account for both the actual indication and bleeding risk, particularly in complicated pericardial lesions.

Clinical manifestations, medical history and physical examination

Incidental detection is a common mode of presentation. A mass may be found during echocardiography, chest CT or MRI performed for another indication. In symptomatic patients, dyspnea and chest pain are common reasons for investigation but remain nonspecific. Clinical assessment must establish whether there is a relationship with obstruction, dysfunction, coronary compression, arrhythmia or effusion, without automatically attributing every coexisting cardiac complaint to the lesion.

The medical history investigates symptom onset and progression, functional limitation, palpitations, syncopal episodes and previous embolic manifestations. Earlier examinations documenting growth and vascular changes are useful. A history of extracardiac cancer raises the differential diagnosis of a hypervascular metastasis; previous operations or procedures may suggest an organized hematoma or acquired vascular alteration. Antithrombotic therapy and a history of bleeding are important in planning the work-up.

In the fetus and child, a mass may be discovered before symptoms occur or be associated with tachycardia, feeding difficulties, poor growth and signs of heart failure. Significant effusion or impaired fetal cardiac function requires surveillance and planning of care at birth. The presence of cutaneous or visceral vascular lesions warrants attention, but the histological diagnosis of a cardiac mass cannot be inferred from the appearance of a concurrent skin lesion.

The physical examination assesses blood pressure, rhythm, perfusion and signs of pulmonary or systemic congestion. Murmurs due to obstruction or regurgitation may be present; a continuous sound related to abnormal vascular flow is possible but neither constant nor specific. In pericardial presentations, signs of impaired filling are sought and echocardiography is performed promptly if the patient is unstable. A normal examination is compatible with a small hemangioma and does not resolve the question of its composition.

Multimodality imaging and differential diagnosis

Echocardiography identifies location, size, attachment and mobility. Echogenicity varies: a compact lesion may look solid, while large vascular spaces can produce a heterogeneous appearance. Color Doppler may show internal flow, but a weak signal does not exclude vascularization, particularly within low-flow cavities. Echocardiographic contrast agents, when appropriate and available, may help distinguish a perfused mass from thrombotic material. Assessment must include valves, ventricular function and the pericardial space.

Transesophageal echocardiography is selected when mass location, valvular attachment or atrial relationships require greater detail. It is also useful for perioperative assessment and checking for residual lesions or valvular consequences. Its contribution is chiefly anatomical and dynamic; cross-sectional techniques are often needed to characterize the vasculature and extracavitary extent comprehensively. The various tests should answer complementary questions rather than repeat information already adequately established.

On magnetic resonance imaging, high T2 signal is common, consistent with vascular and water content, whereas T1 signal depends on composition and any associated hemorrhage. Perfusion and postcontrast enhancement may be intense, but enhancement kinetics vary: a slow-flow cavernous component may fill later than a capillary network. Thrombosis and fibrosis create less-perfused areas. An acquisition limited to the initial phase may therefore underestimate the vascular nature of the lesion.
Cine images clarify protrusion, compression and relative movement with respect to the chambers. Joint assessment of perfusion, tissue sequences and late enhancement allows a stronger hypothesis than simply observing a bright mass on T2-weighted images.

Contrast-enhanced CT depicts relationships with the coronary arteries, great vessels and pericardium. Acquisition phases must match the clinical question, because appearance changes as vascular channels fill. Coronary CT angiography may identify feeding vessels and critical relationships; in selected cases, invasive angiography further defines the blood supply, showing an area of tumor enhancement often termed a tumor blush. This finding demonstrates vascularization but is not specific for hemangioma.

A hypervascular mass in the region of the great vessels or cardiac grooves requires comparison with cardiac paraganglioma. Location, catecholamine biochemistry and functional imaging can radically change the diagnostic pathway and procedural preparation. Cardiac angiosarcoma is considered particularly when infiltrative growth, necrosis, effusion or signs of dissemination are present; here too, differentiation depends on the overall findings and pathology, not on contrast intensity alone.

The differential diagnosis also includes vascular malformations, coronary fistulas, aneurysms, other benign masses and hypervascular metastases. A formation directly connected to a vessel may represent vascular dilatation rather than neoplasia; thrombus or organized hematoma may mimic poorly perfused portions of a hemangioma. Recognizing vascular continuity and the various components prevents interpretations based on a single image. For valvular lesions, fibroelastoma and vegetations must also be considered, with infectious investigations only when clinically relevant.

Histological confirmation is often obtained from the resected specimen. Preliminary biopsy must be considered with particular caution because of bleeding risk and the possibility of nonrepresentative sampling. If the mass is highly vascularized, sampling is not an automatic diagnostic step. The multidisciplinary team determines whether imaging is sufficient to guide management, resection is already indicated, or targeted sampling could change treatment at an acceptable risk; suspicion of paraganglioma must be resolved before manipulating the lesion.

Further investigations and definition of extent

Once a vascular nature is considered likely, the blood supply and drainage, intramural extent and relationships with structures that must be preserved are defined. Coronary assessment is particularly important when the tumor receives branches sharing their origin with the myocardial circulation: interrupting a feeding vessel requires understanding which tissue it perfuses. Any arteriovenous communication must be described anatomically and functionally, especially when an effect on volume load is suspected.

Rhythm monitoring is tailored to presentation. An ECG documents baseline abnormalities; prolonged recordings are useful for intermittent palpitations and syncope. When dysfunction or pain is present, investigations seek a consistent mechanism, distinguishing consequences of the mass from coexisting heart disease. Blood count, renal function and coagulation tests contribute to procedural assessment and evaluation of possible bleeding, but no specific blood marker can diagnose hemangioma.

The search for extracardiac lesions is guided by the history, clinical examination and available imaging. Suspected syndromic disease or multiple vascular lesions may require dedicated evaluation; a solitary mass with benign features does not in itself require complete oncological staging. Conversely, when malignancy remains a concern, the work-up must also define extracardiac sites and the possibility of safer sampling. The purpose of investigations is to make explicit the hypothesis that will guide treatment.

Treatment: resection, surveillance and selected options

Surgery is generally considered for symptomatic, obstructive or growing masses, those associated with complications, or those with substantial diagnostic uncertainty. Complete removal provides both a definitive diagnosis and local control when anatomical relationships allow it. The decision also depends on bleeding risk and the ability to preserve coronary arteries, valves and myocardium; labeling a lesion benign does not make surgery straightforward when a vascular mass is embedded in essential structures.

The technique requires control of feeding vessels and an approach appropriate to the location. Cardiopulmonary bypass may be needed for intracardiac lesions or those requiring reconstruction, whereas other sites permit different strategies. Extensive resection may involve wall reconstruction, valve repair or vascular reconstruction. Surgical planning should anticipate these possibilities through careful interpretation of imaging rather than dealing with vascularity only after exposing the mass.

When complete removal would cause disproportionate harm, partial resection or conservative management may be discussed. Residual disease must be measurable and followed because natural evolution varies and cannot reliably be predicted from subtype alone. In an asymptomatic patient with a highly probable diagnosis, no functional compromise and substantial operative risk, surveillance is a reasonable choice. Documented growth, new arrhythmias or a change in function require reconsideration of this approach.

Embolization of feeding vessels has been described in selected situations as part of a specialist strategy, but is not a standard treatment applicable to every cardiac hemangioma. Proximity to the coronary circulation can expose the myocardium to ischemia or unintended embolization. A decision requires precise vascular mapping, a specific purpose and an experienced team. The potential benefit regarding bleeding or lesion volume must be weighed against these risks and the surgical alternative.

Drug treatments used for some extracardiac vascular anomalies have very limited, context-dependent evidence in the heart. Reports of response to beta-blockers or other therapies do not establish a general protocol for adult cardiac masses. In particular, the behavior of a proliferative infantile hemangioma must be distinguished from that of a cavernous lesion diagnosed later in life. Any systemic treatment requires an appropriate diagnosis and specialist evaluation; antineoplastic chemotherapy and radiotherapy are not usual options for a resectable conventional hemangioma.

Management simultaneously addresses the cardiac consequences: arrhythmias, heart failure, proven ischemia and pericardial compromise. In tamponade, stabilization and drainage, when indicated, are organized with consideration of the possible vascular origin and required surgical support. Anticoagulants and antiplatelet agents are prescribed for specific indications, not merely because a mass is present. Symptom treatment may stabilize the patient but must remain linked to the decision about controlling the lesion.

Prognosis, recurrence and follow-up

After effective resection, prognosis is generally favorable, especially when functional impairment is reversible. Published reports often describe good recovery and few recurrences, but follow-up duration is inconsistent. The 2025 review specifically highlights limited documentation of long-term outcomes: the absence of recurrence over a short observation period does not prove definitive cure for every presentation. Location, extent and completeness of excision remain the most useful factors for organizing surveillance.

Follow-up documents the operated region, any residual lesion, chamber and valve function, and rhythm. Echocardiography is often sufficient for functional monitoring; CT or MRI is used when characterization and more precise measurements are needed. In observed patients, comparisons should use comparable planes and methods, including contrast kinetics when relevant. No single validated interval exists: the timing and duration of follow-up depend on diagnostic uncertainty, course, anatomy and clinical condition.

The appearance of new symptoms, reproducible growth or unexpected tissue features requires renewed diagnostic and therapeutic discussion. Possible explanations include lesion enlargement, internal thrombosis, bleeding, evolution of a residual lesion or incomplete initial classification. A change must not automatically be labeled malignant transformation: diagnosing a different vascular neoplasm requires specific evidence. Surveillance is especially valuable when histology is unavailable or resection has been limited.

Clinical and procedural complications

Complications include intracardiac obstruction, valvular dysfunction, heart failure, arrhythmias and conduction disorders. Pericardial lesions may be associated with effusion, bleeding and tamponade; rare mobile intracavitary masses may be associated with embolism. A significant abnormal vascular network may interfere with perfusion and hemodynamic load. These events explain why a histologically benign lesion may require urgent treatment if it compromises function.

Procedural risks chiefly involve hemorrhage, coronary injury, wall damage and valvular alteration during biopsy or resection. Occluding a feeding vessel shared with the myocardium may cause ischemia; unplanned sampling may be dangerous even for a relatively small mass. Preliminary recognition of its vascular nature, a differential diagnosis that includes paraganglioma, and multidisciplinary planning are therefore essential parts of treatment, even before a resection technique is chosen.

References
  1. Li W et al. Cardiac Hemangioma: A Comprehensive Analysis of 200 Cases. The Annals of Thoracic Surgery. 2015;99(6):2246-2252.
  2. Munteanu IR et al. Cardiac Hemangiomas: A Five-Year Systematic Review of Diagnosis, Treatment, and Outcomes. Cancers. 2025;17(9):1532.
  3. Brizard C et al. Cardiac hemangiomas. The Annals of Thoracic Surgery. 1993;56(2):390-394.
  4. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  5. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  6. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  7. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  8. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  9. Uzun O et al. Cardiac tumours in children. Orphanet Journal of Rare Diseases. 2007;2:11.
  10. Kurmann R et al. Cardiac Masses Discovered by Echocardiogram; What to Do Next? Structural Heart. 2023;7(4):100154.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.